Asalaser

03/06/2026

Step inside the science of Hilterapia®.

Our new immersive 3D animation reveals how the patented Hilterapia® technology works — from its 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗵𝗶𝗴𝗵-𝗶𝗻𝘁𝗲𝗻𝘀𝗶𝘁𝘆 𝗽𝘂𝗹𝘀𝗲𝗱 𝗡𝗱:𝗬𝗮𝗴 𝗹𝗮𝘀𝗲𝗿 𝘀𝗼𝘂𝗿𝗰𝗲 (1064 nm) to the ultra-high peak powers that make it unique in the field of laser therapy.

Designed to support recovery, regeneration, and performance, Hilterapia® is widely used in sports medicine and rehabilitation to help athletes and patients manage pain, accelerate functional recovery, and return to movement faster.

Its regenerative power is especially effective in chronic conditions:
by 𝘀𝘁𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗮 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗱 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 ➡️ Hilterapia® helps 𝗿𝗲𝗮𝗰𝘁𝗶𝘃𝗮𝘁𝗲 𝘁𝗵𝗲 𝗯𝗼𝗱𝘆’𝘀 𝗻𝗮𝘁𝘂𝗿𝗮𝗹 𝗮𝗻𝘁𝗶-𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗿𝗲𝗽𝗮𝗿𝗮𝘁𝗶𝘃𝗲 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 where healing has slowed down over time.

Watch the future of regenerative laser therapy in motion.

‼️ Want to learn more? Join our two-part Webinar Series on Hilterapia in the Era of Longevity on June 4th and 11th!
📝 https://my.demio.com/ref/umcAB8MyQ4CHZaIj?utm_source=organic_social&utm_campaign=hum

22/05/2026

“The real goal is not just pain reduction. It’s improving the quality of healing.”

In musculoskeletal care, recovery speed, inflammation management, and patient compliance directly impact clinical outcomes.

In this interview, Mark Kingham — chiropractor specialised in integrative sports medicine — explains how integrating MLS®️ Laser Therapy and Hilterapia®️ has improved:
✔️ pain relief
✔️ functional recovery
✔️ tissue healing quality
✔️ patient adherence to treatment

Different technologies. Complementary approaches. One objective: delivering better patient outcomes.

🎥 Watch the full interview: https://www.asalaser.com/en/why-asa/mlsr-laser-therapy-and-hilterapiar-benefits-patients-and-improved-clinical-outcomes (or link in Bio)

//

“Il vero obiettivo non è solo ridurre il dolore. È migliorare la qualità della guarigione.”

Nel trattamento delle patologie muscoloscheletriche, velocità di recupero, modulazione dell’infiammazione e compliance del paziente fanno la differenza nei risultati clinici.

In questa intervista, Mark Kingham — chiropratico specializzato in medicina sportiva integrata — racconta come l’integrazione di MLS®️ Laser Therapy e Hilterapia®️ abbia migliorato:
✔️ sollievo dal dolore
✔️ recupero funzionale
✔️ qualità del tessuto
✔️ aderenza terapeutica

Tecnologie diverse, approcci complementari, un unico obiettivo: ottimizzare il percorso di cura del paziente.

🎥 Guarda l’intervista completa: https://www.asalaser.com/it/perche-asa/laserterapia-mlsr-hilterapiar-benefici-pazienti-miglioramento-risultati-clinici

19/05/2026

⚠️‼️Join our upcoming webinar series: Hilterapia® in the Era of Longevity

💻 Two dedicated online sessions exploring the role of Hilterapia® in the management of geriatric conditions, with insights from international expert.

📅 04/06
Scientific clinical evidence supporting the use of Hilterapia on geriatric conditions
Speaker: Giacomo Granozio Asa

📅 11/06
Advanced application modalities on geriatric conditions
Speaker: Mata Karagianni

📝 Register now and secure your spot: https://my.demio.com/ref/umcAB8MyQ4CHZaIj?utm_source=organic_social&utm_campaign=hum

12/05/2026

ASAlaser is heading to ESTRO 2026 (European SocieTy for Radiotherapy and Oncology) with one goal: raising the standard of supportive care in oncology.

Our team will present the new M-RB1 laser therapy device, developed to support patients undergoing chemotherapy and radiotherapy by helping 𝐫𝐞𝐝𝐮𝐜𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭-𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 and improve their overall clinical care pathway.

Together with our partner ELSE Solution, we look forward to welcoming healthcare professionals and industry leaders

📆 May 15-19
🇸🇪 Stockholmsmässan | Stockholm (Sweden)
📍Booth 39, Hall C05

08/05/2026

🔬 From mechanism to translation: a new step in MLS® laser therapy research

We are proud to share a new publication developed within the ASA Campus Joint Laboratory, in collaboration with the Division of Neonatology, Careggi University Hospital (Florence) and the University of Florence.

👉 https://www.mdpi.com/2076-3271/14/1/152

This study investigates MLS® laser therapy in an advanced ex vivo lung model (precision-cut lung slices)—a system that preserves tissue architecture and cellular interactions, bridging the gap between in vitro and in vivo research.

Key insights:

Significant reduction of IL-6 and TNF-α
Comparable energy, different outcomes depending on delivery parameters
Evidence that power density and exposure time influence biological response

Why it matters:
Understanding how laser energy interacts with complex tissues is essential to move from empirical use to mechanism-driven, reproducible protocols.

This work contributes to building a stronger scientific foundation for the future development of MLS® laser therapy.

04/05/2026

Wound management remains one of the most demanding challenges in healthcare.

Chronic lesions, diabetic ulcers, delayed post-surgical healing, ...
Too often, conventional approaches are not enough to actively drive tissue repair.

At EWMA 2026 - European Wound Management Association - EWMA , ASA will be there to discuss a different perspective.

📍 Bremen (Germany 🇩🇪) | May 6–8
📍 Hall 5 – Stand F03

We will explore how MLS® Laser Therapy supports wound healing at the biological level:
✅ modulation of inflammation and oedema
✅ stimulation of cellular activity and tissue regeneration
✅ optimization of healing timelines and clinical workflow

An approach designed not only to manage wounds—but to actively promote repair.

If you are looking to go beyond standard care and address the underlying mechanisms of healing, this is the conversation to have.
See you in Bremen!

02/05/2026

This May, we’re on the move—connecting with clinicians, researchers, and partners across the globe to share knowledge, explore new applications, and bring science closer to everyday practice.

Join us at the upcoming events and discover how our technologies make a real difference where it matters most. 👇

EXPO
06–08 | EWMA-DEWU 2026 – Bremen 🇩🇪
13 | PBM National Seminar – Villejui f🇫🇷
15–19 | ESTRO 2026 – Stockholm 🇸🇪

TRAININGS
22–23 | Hilterapia – Lima (A. Castañon) 🇵🇪
28–31 | Hilterapia – Taiwan (M. Karagianni) 🇹🇼

👉 Visit us and see innovation in action.

24/04/2026

Laser therapy today requires more than effective technology: it demands methodology, validation, and measurable outcomes.

With ASAlaser, medical specialists can rely on:
🔬 clinically 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐞𝐝 𝐩𝐫𝐨𝐭𝐨𝐜𝐨𝐥𝐬 supported by scientific evidence
⚠ technologies developed in compliance with 𝐄𝐔 𝐌𝐃𝐑 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬, ensuring maximum therapeutic safety
📊 tangible, trackable 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 over time
⚙️ solutions designed to integrate seamlessly into daily clinical practice, with 𝐜𝐨𝐧𝐬𝐢𝐬𝐭𝐞𝐧𝐜𝐲 𝐚𝐧𝐝 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲

An approach that combines research, engineering, and clinical expertise, transforming therapy into real value for both physician and patient.

Find out more about our scientific approach: https://www.asalaser.com/en/research-training

22/04/2026

🚀 3D bioprinting + laser therapy: a new frontier in wound care

A new preclinical study from the ASA Campus Joint Lab (with University of Florence) explores what happens when bioprinting meets photobiomodulation.

🧬 The result?
A combined approach that showed:
✔️ better tissue regeneration
✔️ improved graft integration
✔️ less fibrosis

Not just laser as support — but part of a regenerative strategy.

Even more interesting: potential future applications in extreme settings like space medicine 🌌

This is early-stage research, but it opens exciting possibilities for the future of tissue repair.

🔗 Read the full article: https://www.asalaser.com/en/company/blog/complex-wound-healing-3d-bioprinting-and-laser-therapy?utm_source=meta&utm_medium=post&utm_campaign=

18/12/2025

Proud to see MiS laser joining new clinics ✨🇩🇪
A laser device that acts on pain and its causes, combining enhanced MLS® and Hilterapia® for effective and long-lasting results, especially in the treatment of neuropathic pain.

Thank you for choosing ASA technology Base Camp Physio 💙

Modernstes Asalaser Lasergerät MiS bei uns im Einsatz.

Lasertherapie an chronischen neuropathischen Schmerzen zeigt eine deutliche und langanhaltende Reduktion der Schmerzsymptome, begleitet von einer Wiedererlangung der Funktionstüchtigkeit.

Aus biologischer Sicht begünstigt die Behandlung mit MiS die Heilung beschädigter Nervenfasern im Bereich der Verletzung, was histologische und immunhistochemische Analysen bestätigen. Insbesondere ist die Neustrukturierung der Nervenhülle sowohl für den Trophismus des Nervs sowie für die Leitfähigkeit von Bedeutung.